N-(4-(4-(2-methoxyphenyl)piperazin-1-yl)butyl)benzamide | 115338-28-8

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二嗪烷类
• 英文名称: N-(4-(4-(2-methoxyphenyl)piperazin-1-yl)butyl)benzamide
• 英文别名: N-[4-[4-(2-methoxyphenyl)piperazin-1-yl]butyl]benzamide
• CAS: 115338-28-8
• 化学式: C₂₂H₂₉N₃O₂
• 分子量: 367.491
• InChiKey: JYOIFSSKXBNYGV-UHFFFAOYSA-N

物化性质

• 熔点：
  108-110 °C(Solv: acetonitrile (75-05-8))
• 沸点：
  583.7±50.0 °C(Predicted)
• 密度：
  1.106±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  3.5
• 重原子数：
  27
• 可旋转键数：
  8
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.41
• 拓扑面积：
  44.8
• 氢给体数：
  1
• 氢受体数：
  4

反应信息

• 作为产物：
  描述：

  N-(4-溴丁基)邻苯二甲酰亚胺 在 一水合肼 作用下， 以 乙醇 、 xylene 为溶剂， 反应 30.0h， 生成 N-(4-(4-(2-methoxyphenyl)piperazin-1-yl)butyl)benzamide
  参考文献：
  名称：

  Arylpiperazine derivatives as high-affinity 5-HT1A serotonin ligands

  摘要：

  Although simple arylpiperazines are commonly considered to be moderately selective for 5-HT1B serotonin binding sites, N4-substitution of such compounds can enhance their affinity for 5-HT1A sites and/or decrease their affinity for 5-HT1B sites. A small series of 4-substituted 1-arylpiperazines was prepared in an attempt to develop agents with high affinity for 5-HT1A sites. Derivatives where the aryl portion is phenyl, 2-methoxyphenyl, or 1-naphthyl, and the 4-substituent is either a phthalimido or benzamido group at a distance of four methylene units away from the piperazine 4-position, display high affinity for these sites. One of these compounds, 1-(2-methoxyphenyl)-4-[4-(2-phthalimido)butyl]piperazine (18), possesses a higher affinity than 5-HT and represents the highest affinity (Ki = 0.6 nM) agent yet reported for 5-HT1A sites.

  DOI：

  10.1021/jm00118a018

文献信息

• [EN] RADIOLABELED COMPOUNDS AND METHODS THEREOF<br/>[FR] COMPOSÉS RADIOMARQUÉS ET LEURS PROCÉDÉS
  申请人：GE HEALTHCARE LTD

  公开号：WO2011150183A1

  公开（公告）日：2011-12-01

  The present invention relates to radiodiagnostic compounds, methods of making those compounds, and methods of use thereof as imaging agents for preferably a HA serotonin 5-HT1A receptor for use in PET or SPECT, preferably PET. Compositions comprising an imaging-effective amount of radiolabeled compounds are also disclosed. The present invention also relates to non-radiolabeled compounds, methods of making those compounds, and methods of use thereof to treat various neurological and/or psychiatric disorders.

  本发明涉及放射诊断化合物，制备这些化合物的方法，以及将其用作HA血清素5-HT1A受体的成像剂，用于PET或SPECT，更好地使用PET的方法。还披露了包含放射标记化合物的成像有效量的组合物。本发明还涉及非放射标记化合物，制备这些化合物的方法，以及将其用于治疗各种神经学和/或精神疾病的方法。
• RADIOLABELED COMPOUNDS AND METHODS THEREOF
  申请人：Newington Ian Martin

  公开号：US20130064770A1

  公开（公告）日：2013-03-14

  The present invention relates to radiodiagnostic compounds, methods of making those compounds, and methods of use thereof as imaging agents for preferably a HA serotonin 5-HT1A receptor for use in PET or SPECT, preferably PET. Compositions comprising an imaging-effective amount of radiolabeled compounds are also disclosed. The present invention also relates to non-radiolabeled compounds, methods of making those compounds, and methods of use thereof to treat various neurological and/or psychiatric disorders.

  本发明涉及放射性诊断化合物、制备这些化合物的方法以及将其用作成像剂的方法，优选地用于PET或SPECT，特别是HA 5-HT1A受体，其中包括成像有效量的放射性标记化合物的组合物。本发明还涉及非放射性标记化合物、制备这些化合物的方法以及将其用于治疗各种神经和/或精神障碍的方法。
• First Structure−Activity Relationship Study on Dopamine D₃ Receptor Agents with <i>N</i>-[4-(4-Arylpiperazin-1-yl)butyl]arylcarboxamide Structure
  作者：Marcello Leopoldo、Enza Lacivita、Nicola A. Colabufo、Marialessandra Contino、Francesco Berardi、Roberto Perrone

  DOI：10.1021/jm050729o

  日期：2005.12.1

  Structure-affinity relationships of N-[4-(4-arylpiperazin-1-yl)butyl]arylcarboxamides as D-3 receptor ligands have been well characterized but not structure-activity relationships. In a first attempt to clarify this issue, seven 1-(2,3dichlorophenyl)piperazine derivatives and their 2-methoxyphenyl counterparts were prepared by varying the arylcarbox-amide moiety. They were tested for D3 receptor binding affinities and in the Eu-GTP binding assay in order to evaluate their intrinsic activity. We have found that the intrinsic activity strongly depended on the nature of the arylearboxamide moiety.
• GLENNON, RICHARD A.;NAIMAN, NOREEN A.;LYON, ROBERT A.;TITELER, MILT, J. MED. CHEM., 31,(1988) N 10, C. 1968-1971
  作者：GLENNON, RICHARD A.、NAIMAN, NOREEN A.、LYON, ROBERT A.、TITELER, MILT

  DOI：——

  日期：——
• Arylpiperazine derivatives as high-affinity 5-HT1A serotonin ligands
  作者：Richard A. Glennon、Noreen A. Naiman、Robert A. Lyon、Milt Titeler

  DOI：10.1021/jm00118a018

  日期：1988.10

  Although simple arylpiperazines are commonly considered to be moderately selective for 5-HT1B serotonin binding sites, N4-substitution of such compounds can enhance their affinity for 5-HT1A sites and/or decrease their affinity for 5-HT1B sites. A small series of 4-substituted 1-arylpiperazines was prepared in an attempt to develop agents with high affinity for 5-HT1A sites. Derivatives where the aryl portion is phenyl, 2-methoxyphenyl, or 1-naphthyl, and the 4-substituent is either a phthalimido or benzamido group at a distance of four methylene units away from the piperazine 4-position, display high affinity for these sites. One of these compounds, 1-(2-methoxyphenyl)-4-[4-(2-phthalimido)butyl]piperazine (18), possesses a higher affinity than 5-HT and represents the highest affinity (Ki = 0.6 nM) agent yet reported for 5-HT1A sites.